BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with life-threatening diseases. Our principal technology platform centers on targeted protein degradation, as well as PHM® ‘molecular glues’, that enable the design of small molecules to regulate protein equilibrium. This technology is designed to utilize the body’s own protein disposal system to selectively degrade and remove disease-causing proteins. It has potential applicability to a broad range of diseases, including targets that have to date been considered ‘undruggable’.
Location: United States, New York
Employees: 11-50
Total raised: $127M
Founded date: 2008
Investors 2
| Date | Name | Website |
| 08.11.2021 | Lumira Ven... | lumiravent... |
| 15.09.2021 | SR One | srone.com |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 10.06.2021 | Series E | $92M | - | socaltech.... |
| 28.07.2020 | Series D | $35M | - | socaltech.... |
Mentions in press and media 12
| Date | Title | Description | Source |
| 06.08.2021 | BioTheryX Announces Appointments of Three New Members to its... | SAN DIEGO, Aug. 6, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on creat... | prnewswire... |
| 09.06.2021 | BioTheryX Announces First Patient Dosed with BTX-A51 in Phas... | SAN DIEGO, June 9, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degra... | prnewswire... |
| 20.05.2021 | BioTheryX Announces $92M Series E Financing to Accelerate De... | SAN DIEGO, May 20, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degra... | prnewswire... |
| 20.05.2021 | BioTheryX has announced a $92M Series E to accelerate develo... | - | connect.or... |
| 20.05.2021 | BioTheryX Gets $92M | San Diego-based BioTheryX, which is developing protein degradation technology for use in creating ca... | socaltech.... |
| 18.05.2021 | BioTheryX Announces Expansion of Scientific Advisory Board w... | SAN DIEGO, May 18, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degra... | prnewswire... |
| 07.04.2021 | BioTheryX Announces Expansion of Scientific Advisory Board | SAN DIEGO, April 7, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degr... | prnewswire... |
| 01.02.2021 | BioTheryX Appoints Jamie Donadio as Chief Financial Officer | SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degra... | prnewswire... |
| 29.07.2020 | BioTheryX Finds $35M More | San Diego-based BioTheryX, a biotechnology company focused on protein modulation, has raised $35M in... | socaltech.... |
| 28.07.2020 | BioTheryX Raises $35M in Series D Financing | BioTheryX, Inc., a San Diego, CA-based clinical stage biotechnology company, closed a $35m Series D ... | finsmes.co... |
Show more